Shelter Pharma reported a 44.35% year-on-year increase in revenue from operations to ₹73.13 crore for FY26, driven by a diversified product portfolio and expanded market presence. The company posted a net profit of ₹9.03 crore for the year, reflecting a 24.72% growth compared to the previous year. Management attributed the performance to strong execution in the human and veterinary healthcare segments and a focus on Ayurvedic and herbal solutions.

The company remains almost debt-free, with borrowings at ₹0.8 crore as of March 26, 2026, and reserves growing by 92.62% to ₹60.02 crore. Shelter Pharma has outlined an ambitious growth trajectory under its Vision 2030, targeting annual revenues of ₹200 crore through capacity expansion, new product launches, and deeper global market penetration. The firm recently acquired land near Himmatnagar, Gujarat, to establish a second manufacturing facility.

Financial Performance

Shelter Pharma's financial highlights for FY26 show consistent top-line growth and improving profitability metrics. The EBITDA for the year stood at ₹12.72 crore, while the Profit Before Tax rose 26.24% to ₹12.22 crore.

The company reported a 3-year compounded revenue growth of 26% and a Return on Capital Employed (ROCE) averaging 25.74% over the same period. The EBITDA margin for FY26 was 17.39%.

Strategic Expansion

As part of its long-term strategy, Shelter Pharma is investing in innovation and product development, focusing on nutraceuticals and advanced formulations. The upcoming manufacturing unit in Gujarat is expected to significantly enhance production capacity. The company currently exports to over 10 countries, including the UK, Egypt, Kuwait, and Bangladesh, and maintains a pan-India distribution network.

Shelter Pharma has successfully completed the manufacturing of an export order worth USD 141,600 for Joemega Capsules and commenced dispatch to Sudan. The order was secured from Taha Drugs & Chemicals Co. Ltd, with products valued at USD 118,634 already shipped as of June 8, 2026. The balance quantity is being dispatched according to the shipment schedule.

The disclosure was made to BSE Limited under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company informed the exchange that the manufacturing process for the order is now complete.

Order Details

The export order involves the supply of Joemega Capsules to Sudan. The total order value stands at USD 141,600, with a significant portion already delivered to the client.

The filing was signed by Mustaqim Nisarahmed Sabugar, Managing Director of Shelter Pharma Limited, on June 8, 2026.